- Intellia Therapeutics has secured FDA priority review for its hereditary angioedema gene editing therapy lonvo z and reported fresh positive trial data, while also advancing phase 3 programs in ATTR polyneuropathy and cardiomyopathy.
- The business is positioning lonvo z as a potential one time in vivo CRISPR treatment in a market currently served by high cost chronic therapies. This approach could reshape how hereditary angioedema care is delivered and paid for if uptake and payer coverage align with expectations.
- We will now see how Intellia Therapeutics’ FDA priority review for lonvo z influences the broader investment narrative around its pipeline.
Spot other gene editing and high-risk, high-reward biotech opportunities on our hand…






